Drwiega, Emily N.
Rodvold, Keith A. http://orcid.org/0000-0002-7200-7346
Article History
Accepted: 29 November 2021
First Online: 4 January 2022
Declarations
:
: This response was not funded in whole or in part by any research grant or funding body.
: Emily Drwiega has no conflicts of interest that are directly relevant to the content of this letter. Keith Rodvold has conducted research and/or served as a consultant for intrapulmonary studies discussed in this letter for Cempra Pharmaceuticals, Cubist Pharmaceuticals, Durata Therapeutics, Entasis Therapeutics, GlaxoSmithKline, Ortho-McNeil Pharmaceutical, Paretek Pharmaceuticals, Shionogi & Co., The Medicine Company/Rempex, and Wockhardt Ltd. Keith Rodvold has served on advisory boards, speaking bureaus, or as a consultant for Merck Inc., Shionogi & Co., Sinovent, Spero Therapeutics, The Medicine Company/Qpex Biopharma, and Venatorx Pharmaceuticals.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Both authors made substantial contributions to the conception, drafting, and critically revising of the manuscript for important intellectual content. Both authors approved the final version of the manuscript.
Free to read: This content has been made available to all.